Organon & Co. $OGN Position Boosted by Tidal Investments LLC

Tidal Investments LLC grew its holdings in Organon & Co. (NYSE:OGN) by 18.1% during the second quarter, Holdings Channel.com reports. The firm owned 285,099 shares of the company’s stock after buying an additional 43,687 shares during the period. Tidal Investments LLC’s holdings in Organon & Co. were worth $3,860,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in OGN. Cetera Investment Advisers increased its stake in Organon & Co. by 1.7% in the 1st quarter. Cetera Investment Advisers now owns 48,073 shares of the company’s stock valued at $288,000 after buying an additional 788 shares during the period. GAMMA Investing LLC lifted its position in Organon & Co. by 69.8% in the 2nd quarter. GAMMA Investing LLC now owns 5,782 shares of the company’s stock worth $78,000 after buying an additional 2,376 shares in the last quarter. Allied Private Wealth LLC acquired a new stake in shares of Organon & Co. during the 2nd quarter valued at $33,000. Poehling Capital Management INC. boosted its stake in shares of Organon & Co. by 1.3% during the 1st quarter. Poehling Capital Management INC. now owns 219,288 shares of the company’s stock valued at $1,314,000 after buying an additional 2,796 shares during the period. Finally, Royce & Associates LP grew its holdings in shares of Organon & Co. by 6.0% during the 4th quarter. Royce & Associates LP now owns 59,878 shares of the company’s stock valued at $429,000 after acquiring an additional 3,373 shares in the last quarter. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, August 3rd. Five research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average target price of $11.40.

Organon & Co. Stock Up 0.0%

Shares of Organon & Co. stock opened at $13.64 on Tuesday. The firm has a market cap of $3.58 billion, a price-to-earnings ratio of 17.72, a P/E/G ratio of 1.26 and a beta of 1.52. The stock has a 50-day simple moving average of $13.63 and a 200-day simple moving average of $11.59. Organon & Co. has a 52-week low of $5.69 and a 52-week high of $13.78. The company has a debt-to-equity ratio of 8.43, a current ratio of 1.95 and a quick ratio of 1.44.

Organon & Co. Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 10th. Shareholders of record on Friday, August 14th were paid a $0.02 dividend. The ex-dividend date was Friday, August 14th. This represents a $0.08 dividend on an annualized basis and a yield of 0.6%. Organon & Co.’s payout ratio is 10.39%.

Organon & Co. Company Profile

Organon & Co is a global healthcare company focused on improving the health and well-being of women throughout their lives. Its women’s health portfolio includes contraceptive products such as Nexplanon and NuvaRing, as well as fertility treatments and medicines used in reproductive health.

The company also markets biosimilars and a portfolio of established medicines across areas including cardiovascular disease, respiratory conditions, dermatology, pain management and allergy. Its products are distributed in markets around the world, with a particular focus on expanding access to medicines in international and emerging markets.

Organon was established as an independent company through a spin-off from Merck & Co in June 2021.